What is Eledon Pharmaceuticals, Inc.'s (ELDN) StockRank?

MoatMap's StockRank for Eledon Pharmaceuticals, Inc. (ELDN) is 39/100, with a Hold signal. This is a composite score combining Quality (35), Value (28), and Momentum (67) factor ranks across MoatMap's 19,000+ stock universe.

Does Eledon Pharmaceuticals, Inc. have an economic moat?

Eledon Pharmaceuticals, Inc. (ELDN) has a Quality factor score of 35/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Eledon Pharmaceuticals, Inc. a buy, hold, or sell?

MoatMap's current signal for Eledon Pharmaceuticals, Inc. (ELDN) is Hold, based on a StockRank of 39/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Eledon Pharmaceuticals, Inc. in?

Eledon Pharmaceuticals, Inc. (ELDN) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

ELDN

HOLDREMOVE

Eledon Pharmaceuticals, Inc. · Healthcare · United States · $299M · Avg Vol: $4M/d

StockRank

P/E (TTM)

—

ROE

-72.7%

D/E

0.0x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Eledon Pharmaceuticals is a clinical-stage biotech. It lacks commercialized products, validated manufacturing assets, or alignment with our CDMO theme, making it too speculative for our quality-focused book.

COMPANY DESCRIPTION

Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to developing novel immunology therapies for patients with autoimmune diseases and organ transplant recipients. The company's lead therapeutic candidate focuses on inhibiting the CD40L pathway, aiming to prevent organ rejection and treat severe autoimmune conditions. It distinguishes itself by targeting critical immune checkpoints with the potential to offer safer and more effective treatment options for immune-mediated diseases.

FINANCIAL SUMMARY

Year	2022	2023	2024	2025	CAGR
Revenue	0	0	0	0	—
EPS	-6.16	-3.74	-0.66	-0.52	—
Shares	14M	24M	60M	75M	+447.5%
Debt	746,000	383,000	954,000	641,000	-4.9%
Equity	84M	7M	62M	81M	-1.2%
Op CF	-28M	-40M	-47M	-62M	—
Inv CF	0	-45M	-70M	11M	—
Fin CF	0	33M	134M	54M	—

PRICE (1M)-3.3%

SMA 50SMA 200

$3.57

RSI (14)

35.7

52W High

$4.60

From 52W High

0.8%

SCORE BREAKDOWN

Quality

ROIC

-55.3%12.5

ROE

-72.7%11.2

GP/Assets

—N/A

Op. Margin

0.0%40.6

FCF/Assets

-23.5%13.6

Piotroski

—7.2

Int. Cover

—N/A

D/E Ratio

0.01x92.2

Current Ratio

8.44x83.6

Value

P/E (TTM)

—N/A

EV/EBITDA

—N/A

P/FCF

—N/A

P/B

2.7x44.4

P/S

—N/A

Div Yield

—N/A

Momentum

52W High %

78%70.5

RS 6M

102%97.7

SMA 50/200

1.34x95.2

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

+6%25.2

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$299M

P/E (Forward)

-4.9x

Gross Margin

0.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ELDN are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
ELDN	Eledon Pharmaceuticals, Inc.(you)	$299M	39	HOLD
SRZN	Surrozen, Inc.	$304M	40	HOLD
IRD	Opus Genetics, Inc.	$342M	39	HOLD
MGNX	MacroGenics, Inc.	$268M	40	HOLD
FATE	Fate Therapeutics, Inc.	$307M	35	HOLD
ARTV	Artiva Biotherapeutics, Inc.	$370M	39	HOLD
PRLD	Prelude Therapeutics Incorporated	$313M	35	SELL
NERV	Minerva Neurosciences, Inc.	$233M	38	HOLD
SABS	SAB Biotherapeutics, Inc.	$273M	34	SELL
XFOR	X4 Pharmaceuticals, Inc.	$390M	36	HOLD

Peer medians: ROE -21.9% · P/E 25.1x · Gross margin 44.3%

Eledon Pharmaceuticals, Inc. (ELDN) — Stock Score Summary

Eledon Pharmaceuticals, Inc. (ELDN) has a MoatMap StockRank of 39/100 based on Quality (35/100), Value (28/100), and Momentum (67/100) factor scores. The current signal is HOLD. Eledon Pharmaceuticals is a clinical-stage biotech. It lacks commercialized products, validated manufacturing assets, or alignment with our CDMO theme, making it too speculative for our quality-focused book.

Key Financial Metrics

Price	$3.57
Market Cap	$299M
P/E (Forward)	-4.94
Price/Book	2.70
Return on Equity	-72.7%
Return on Invested Capital	-55.3%
Debt/Equity	0.55
Gross Margin	0.0%
Operating Margin	0.0%
Free Cash Flow	$-40M

Eledon Pharmaceuticals, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Eledon Pharmaceuticals, Inc.’s (ELDN) StockRank?: MoatMap’s StockRank for Eledon Pharmaceuticals, Inc. (ELDN) is 39/100, with a Hold signal. It is a composite of Quality (35), Value (28), and Momentum (67) factor ranks across MoatMap’s 19,000+ stock universe.
Does Eledon Pharmaceuticals, Inc. have an economic moat?: Eledon Pharmaceuticals, Inc. (ELDN) has a Quality factor score of 35/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Eledon Pharmaceuticals, Inc. a buy, hold, or sell?: MoatMap’s current signal for Eledon Pharmaceuticals, Inc. (ELDN) is Hold, based on a StockRank of 39/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Eledon Pharmaceuticals, Inc. in?: Eledon Pharmaceuticals, Inc. (ELDN) operates in the Healthcare sector, specifically the Biotechnology industry (United States).